1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Nevro Corp.
  6. News
  7. Summary
    NVRO   US64157F1030


Delayed Nyse  -  04:00 2022-08-08 pm EDT
48.96 USD   +3.93%
08/04Wells Fargo Securities Adjusts Nevro's Price Target to $86 From $90, Reiterates Overweight Rating
08/04Piper Sandler Adjusts Nevro's Price Target to $45 From $64, Maintains Neutral Rating
08/03NEVRO : Q2 Earnings Snapshot
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nevro Announces Update in Patent Litigation with Boston Scientific

11/01/2021 | 05:33pm EDT

REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891,085 and 8,019,439) directed to ways of manufacturing spinal cord stimulation (SCS) leads, which Nevro obtains from a third-party supplier.  Two other Boston Scientific lead patents (8,646,172 and 8,650,747) were not infringed.  The jury awarded Boston Scientific $20 million.  This decision has no commercial implications or would otherwise impose any restrictions on any current or future Nevro products, and the jury award is an amount of money that will not have a material impact on Nevro's business. 

"We disagree with the finding by the jury and plan to appeal," said Kashif Rashid, Nevro's General Counsel.

Nevro's Chairman and CEO, Keith Grossman, stated: "It is important to put this lawsuit into the proper context.  The suit regarding lead patents by Boston Scientific was in retaliation for the 2016 lawsuit Nevro filed to stop Boston Scientific from launching a 10kHz spinal cord stimulation system, which would blatantly and directly infringe Nevro's core intellectual property.  This lawsuit has absolutely no implications on Nevro's commercial efforts for current or planned products, and is directed to manufacturing methods implemented by our third-party supplier.  Nevro will continue to be the exclusive provider of HFX with 10 kHz Therapy, which the FDA determined to be superior to Boston Scientific's SCS therapy."

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.  Nevro's proprietary 10 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies.  The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. 

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com


View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-update-in-patent-litigation-with-boston-scientific-301413427.html

SOURCE Nevro Corp.

© PRNewswire 2021
All news about NEVRO CORP.
08/04Wells Fargo Securities Adjusts Nevro's Price Target to $86 From $90, Reiterates Overwei..
08/04Piper Sandler Adjusts Nevro's Price Target to $45 From $64, Maintains Neutral Rating
08/03NEVRO : Q2 Earnings Snapshot
08/03NEVRO : Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidanc..
08/03NEVRO CORP Management's Discussion and Analysis of Financial Condition and Results of ..
08/03Nevro Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 3..
08/03NEVRO : Second Quarter 2022 Earnings Presentation
08/03Earnings Flash (NVRO) NEVRO Posts Q2 Revenue $104.2M
08/03Earnings Flash (NVRO) NEVRO Posts Q2 Revenue $104.2M
08/03TRANSCRIPT : Nevro Corp., Q2 2022 Earnings Call, Aug 03, 2022
More news
Analyst Recommendations on NEVRO CORP.
More recommendations